View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 6, 2018updated 12 Jul 2022 1:13pm

Regenera Pharma enrols first patient in Phase lll trial of RPh201

Regenera Pharma has enrolled the first patient in a Phase lll trial of RPh201 in the US for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION), a type of stroke of the optic nerve.

Regenera Pharma has enrolled the first patient in a Phase lll trial of RPh201 in the US for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION), a type of stroke of the optic nerve.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Supported by fast-track designation from the US Food and Drug Administration (FDA), the multicentre, double-blind, placebo-controlled trial aims to enrol 234 patients diagnosed with NAION at least one year prior to enrolment into the study.

During the trial, patients will be randomised and receive twice-weekly injections of RPh201 or placebo for a period of six months.

The trial’s primary endpoint is the proportion of patients with visual acuity improving by three lines or more from baseline to week 26.

Set to be conducted in 12 centres across the US, the trial is expected to provide final results in the last quarter of next year.

The Phase lll trial chair Dr Leonard Levin said: “Several thousand people have irreversible visual loss from NAION each year in the US, and the likelihood of improvement after the first six months is very low.

“This new study will help determine the potential for RPh201 to become the first drug shown to restore vision in these patients.”

“This new study will help determine the potential for RPh201 to become the first drug shown to restore vision in these patients.”

RPh201 is a well-defined extract from gum mastic, which is purified, formulated and stabilised in a proprietary process developed by Regenera Pharma.

Furthermore, Regenera is conducting a Phase lla trial in Canada of RPh201 to treat patients with moderate Alzheimer-related dementia.

Regenera is expected to enrol around 45 to 81 patients for the multicentre, double-blind, placebo-controlled trial.

The enrolled patients will be randomised in a 2:1 ratio to receive twice-weekly subcutaneous injections of RPh201 or placebo over a six-month period.

The trial, which will primarily measure cognitive changes from baseline to six months, is currently dosing patients at five centres in Ontario and Quebec.

Readout of the trial is expected by the second quarter of next year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena